Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience
Year: 2007
Type: article
Study design: Observational Study
Abstract: We analyzed prognostic factors of response, response duration, and possible impact on survival of epoetin alpha, epoetin beta, or darbepoetin alpha (DAR) with or without granulocyte colony-stimulating factor in 403 myelodysplastic syndrome (MDS) patients. Sixty-two percent (40% major and 22% minor) and 50% erythroid responses were seen, and median response duration was 20 and 24 months according to IWG 2000 and 2006 criteria, respectively. Significantly higher response rates were observed with less than 10% blasts, low and int-1 International Prognostic Scoring System (IPSS), red blood cell transfusion independence, serum EPO level less than 200 IU/L, and, with IWG 2006 criteria only, shorter interval between diagnosis and treatment. Significantly longer response duration was associated with major response (IWG 2000 criteria), IPSS low to INT-1, blasts less than 5%, and absence of multilineage dysplasia. Minor responses according to IWG 2000 were reclassified as "nonresponders" or "responders" according to IWG 2006 criteria. However, among those IWG 2000 minor responders, response duration did not differ between IWG 2006 responders and nonresponders. Multivariate adjusted comparisons of survival between our cohort and the untreated MDS cohort used to design IPSS showed similar rate of progression to acute myeloid leukemia in both cohorts, but significantly better overall survival in our cohort, suggesting that epoetin or DAR treatment may have a favorable survival impact in MDS.
Source: Blood
Authors: Sophie Park, Sophie Grabar, Charikleia Kelaidi, Odile Beyne-Rauzy, Françoise Picard, Valérie Bardet, Valérie Coiteux, Geneviève Leroux, Pascale Lepelley, Marie-Thérèse Daniel, Stéphane Cheze, Béatrice Mahé, Augustin Ferrant, Christophe Ravoet, Martine Escoffre-Barbe, Lionel Adès, Norbert Vey, Lina Aljassem, Aspasia Stamatoullas, Lionel Mannone, Hervé Dombret, Keith Bourgeois, Peter Greenberg, Pierre Fenaux, François Dreyfus
Institutions: Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Hôpital Avicenne, Hôpital Purpan, Laboratoire d'hématologie, Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Hôpital Saint-Louis, Centre Hospitalier Universitaire de Caen Normandie, Centre Hospitalier Universitaire de Nantes, Cliniques Universitaires Saint-Luc, Institut Jules Bordet, Hôpital Pontchaillou, Institut Paoli-Calmettes, Les Hôpitaux de Chartres, Centre Hospitalier Universitaire de Rouen, Centre Hospitalier Universitaire de Nice, University of Rochester, Stanford Medicine
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: myelodysplastic syndrome, erythropoietin, epoetin alfa, epoetin beta, darbepoetin alfa, granulocyte colony-stimulating factor, prognostic factors, erythroid response, duration of response, International Prognostic Scoring System, multilineage dysplasia, acute myeloid leukemia progression, overall survival, red blood cell transfusion independence, serum erythropoietin
Open Access status: bronze
OpenAlex ID: W1978522934
